Diamile A. Tavarez

Diamile A. Tavarez

Auto-generated profile, based on publicly available information

Diamile A. Tavarez

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDivya Ramchandani
Divya Ramchandani
MBMirela Berisa
Mirela Berisa
DTDiamile A. Tavarez
Diamile A. Tavarez
ZLZhuoning Li
Zhuoning Li
MMMatthew Miele
Matthew Miele
VMVivek Mittal
Vivek Mittal
Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has been associated with a significant survival benefit in high-risk triple negative breast cancer (TNBC) patients. Despite these promising data, the mechanisms by which copper depletion impacts metastasis are poorly understood and this remains a major barrier to advancing TM to a randomized phase II trial. Here, using two independent TNBC models, we report a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibit elevated intracellular copper levels and a marked sensitivity to TM. Global proteomic and metabolomic profiling identifies TM-mediated inactivation of Complex IV as the primary metabolic defect in the SOX2/OCT4+ cell population. We also identify AMPK/mTORC1 energy sensor as an important downstream pathway and show that AMPK inhibition rescues TM-mediated loss of invasion. Furthermore, loss of the mitochondria-specific copper chaperone, COX17, restricts copper deficiency to mitochondria and phenocopies TM-mediated alterations. These findings identify a copper-metabolism-metastasis axis with potential to enrich patient populations in next-generation therapeutic trials.